(2009) S100A8/A9: A Janus-faced molecule in cancer therapy and tumorgenesis. European Journal of Pharmacology. pp. 73-83. ISSN 0014-2999
Full text not available from this repository.
Abstract
Correlations exist between the abundance of S100 proteins and disease pathologies. Indeed, this is evidenced by the heterodimeric S100 protein complex S100A8/A9 which has been shown to be involved in inflammatory and neoplastic disorders. However, S100A8/A9 appears as a Janus-faced molecule in this context. On the one hand, it is a powerful apoptotic agent produced by immune cells, making it a very fascinating tool in the battle against cancer. It spears the risk to induce auto-immune response and may serve as a lead compound for cancer-selective therapeutics. In contrast, S100A8/A9 expression in cancer cells has also been associated with tumor development, cancer invasion or metastasis. Clearly, there is a dichotomy and future investigations into the role of S100A8/A9 in cancer biology need to consider both sides of the same coin. (C) 2009 Elsevier B.V. All rights reserved.
Item Type: | Article |
---|---|
Keywords: | Apoptotic agent Chemoattractance Growth arrest Immune escape Metastasis Reactive oxygen species Stress response Tumorgenesis calcium-binding proteins ef-hand proteins nf-kappa-b apoptosis-inducing activity squamous-cell carcinoma peritoneal-exudate cells s100 target specificity gene-expression breast-cancer arachidonic-acid Pharmacology & Pharmacy |
Page Range: | pp. 73-83 |
Journal or Publication Title: | European Journal of Pharmacology |
Journal Index: | ISI |
Volume: | 625 |
Number: | 1-3 |
Identification Number: | https://doi.org/10.1016/j.ejphar.2009.08.044 |
ISSN: | 0014-2999 |
Depositing User: | خانم مهدیه رضائی پور |
URI: | http://eprints.zaums.ac.ir/id/eprint/2792 |
Actions (login required)
![]() |
View Item |